MCID: ADN018
MIFTS: 64

Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 77 56 15 74
Acinar Cell Adenoma 12 74
Adenomas 12 15
Acinic Cell Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 45 D000236
NCIt 51 C2855 C4196
SNOMED-CT 69 32048006 79041005

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pituitary adenoma, prolactin-secreting and villous adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Signaling by GPCR and Gastric cancer. The drugs Scopolamine and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1047)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma, prolactin-secreting 34.4 AIP GNAS MEN1
2 villous adenoma 34.3 BRAF GNAS KRAS
3 pleomorphic adenoma 34.3 PLAG1 PLAGL1 PLAGL2
4 parathyroid adenoma 34.1 CCND1 CDC73 MEN1 RET
5 sebaceous adenoma 34.1 MLH1 MSH2
6 colorectal adenoma 34.0 APC CTNNB1 KRAS MLH1 MSH2
7 silent pituitary adenoma 33.8 AIP MEN1
8 periampullary adenoma 33.7 APC KRAS
9 null pituitary adenoma 33.5 AIP MEN1
10 acromegaly 33.3 AIP GNAS MEN1
11 polyposis syndrome, hereditary mixed, 1 33.2 APC MLH1
12 hyperparathyroidism 1 33.0 CDC73 MEN1
13 familial adenomatous polyposis 1 32.8 APC CTNNB1
14 mutyh-associated polyposis 32.6 APC KRAS SMAD4
15 hyperparathyroidism 2 with jaw tumors 32.6 CCND1 CDC73 MEN1 RET
16 endometrial adenocarcinoma 32.5 CTNNB1 KRAS MLH1
17 multiple endocrine neoplasia, type i 32.5 CDC73 GNAS MEN1 RET
18 parathyroid carcinoma 32.5 CCND1 CDC73 MEN1 RET
19 mismatch repair cancer syndrome 32.3 APC CTNNB1 MLH1 MSH2
20 multiple endocrine neoplasia, type iia 32.3 CDC73 MEN1 RET
21 colorectal cancer 32.2 APC BRAF CCND1 CTNNB1 GNAS KRAS
22 familial adenomatous polyposis 32.1 APC CCND1 CTNNB1 KRAS MLH1 MSH2
23 hyperparathyroidism 31.6 CDC73 MEN1 RET
24 primary hyperparathyroidism 31.3 CCND1 CDC73 MEN1 RET
25 pituitary tumors 30.9 AIP GNAS MEN1
26 adenocarcinoma 30.9 APC BRAF CCND1 CTNNB1 GNAS KRAS
27 papillary carcinoma 30.9 BRAF RET TSHR
28 peutz-jeghers syndrome 30.8 APC CTNNB1 SMAD4
29 carney complex variant 30.7 AIP GNAS MEN1
30 thyroid cancer 30.7 APC BRAF CCND1 CTNNB1 GNAS KRAS
31 lynch syndrome 30.5 APC BRAF CCND1 CTNNB1 KRAS MLH1
32 thyroid cancer, nonmedullary, 2 30.5 BRAF MEN1 RET TSHR
33 renal cell carcinoma, papillary, 1 30.4 BRAF CDC73 MSH2
34 colon adenocarcinoma 30.4 APC CTNNB1 KRAS MLH1
35 familial colorectal cancer 30.3 APC MLH1 MSH2
36 von hippel-lindau syndrome 30.3 CCND1 MEN1 RET
37 hyperplastic polyposis syndrome 30.3 APC BRAF KRAS
38 cholangiocarcinoma 30.3 BRAF CCND1 CTNNB1 KRAS SMAD4
39 gastric cancer 30.2 APC CCND1 CTNNB1 KRAS MLH1 MSH2
40 struma ovarii 30.2 BRAF RET TSHR
41 gastrointestinal stromal tumor 30.2 BRAF CCND1 KRAS MEN1
42 thyroid carcinoma, familial medullary 30.2 KRAS MEN1 RET
43 colorectal adenocarcinoma 30.2 BRAF CTNNB1 KRAS MLH1 MSH2
44 familial isolated hyperparathyroidism 30.1 CDC73 MEN1 RET
45 intestinal disease 30.0 CCND1 CTNNB1 KRAS MLH1 MSH2
46 attenuated familial adenomatous polyposis 30.0 APC MSH2
47 differentiated thyroid carcinoma 29.9 BRAF KRAS RET TSHR
48 hepatoblastoma 29.9 APC CTNNB1 PLAG1
49 ovarian cancer 29.9 BRAF CCND1 CTNNB1 KRAS MLH1 MSH2
50 bladder urothelial carcinoma 29.9 BRAF CCND1 CTNNB1 KRAS MLH1

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

27 (show top 50) (show all 73)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 11.08 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 11.08 CTNNB1 SMAD4 KRAS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 11.08 PLAGL2 BRAF
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 11.08 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 11.08 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 11.08 KRAS
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 11.08 MEN1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 11.08 MLH1 PLAG1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 11.08 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-127 11.08 PLAGL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-128 11.08 MEN1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 11.08 MLH1 RET
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 11.08 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-133 11.08 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 11.08 MLH1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 11.08 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 11.08 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 11.08 PLAG1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 11.08 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 11.08 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-163 11.08 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-164 11.08 RET
23 Increased shRNA abundance (Z-score > 2) GR00366-A-166 11.08 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 11.08 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-176 11.08 RET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 11.08 APC CTNNB1 CCND1 KRAS MEN1 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-192 11.08 APC
28 Increased shRNA abundance (Z-score > 2) GR00366-A-194 11.08 BRAF
29 Increased shRNA abundance (Z-score > 2) GR00366-A-195 11.08 MLH1 SMAD4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-196 11.08 KRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-197 11.08 CTNNB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 11.08 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-202 11.08 APC
34 Increased shRNA abundance (Z-score > 2) GR00366-A-207 11.08 PLAG1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-21 11.08 SMAD4 CCND1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-210 11.08 CCND1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-23 11.08 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-25 11.08 SMAD4 CCND1 PLAGL2 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-29 11.08 APC BRAF
40 Increased shRNA abundance (Z-score > 2) GR00366-A-31 11.08 BRAF
41 Increased shRNA abundance (Z-score > 2) GR00366-A-32 11.08 BRAF
42 Increased shRNA abundance (Z-score > 2) GR00366-A-36 11.08 CCND1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-42 11.08 SMAD4
44 Increased shRNA abundance (Z-score > 2) GR00366-A-43 11.08 SMAD4 MEN1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-46 11.08 SMAD4
46 Increased shRNA abundance (Z-score > 2) GR00366-A-47 11.08 CTNNB1 MEN1 BRAF
47 Increased shRNA abundance (Z-score > 2) GR00366-A-49 11.08 APC CTNNB1 KRAS MEN1 PLAG1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-50 11.08 KRAS
49 Increased shRNA abundance (Z-score > 2) GR00366-A-52 11.08 RET
50 Increased shRNA abundance (Z-score > 2) GR00366-A-54 11.08 SMAD4

MGI Mouse Phenotypes related to Adenoma:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.54 AIP APC BRAF CCND1 CDC73 CTNNB1
2 growth/size/body region MP:0005378 10.51 AIP APC BRAF CCND1 CDC73 CTNNB1
3 endocrine/exocrine gland MP:0005379 10.49 AIP APC BRAF CCND1 CDC73 CTNNB1
4 homeostasis/metabolism MP:0005376 10.48 AIP APC BRAF CCND1 CDC73 CTNNB1
5 digestive/alimentary MP:0005381 10.44 APC BRAF CCND1 CDC73 CTNNB1 KRAS
6 cardiovascular system MP:0005385 10.43 AIP APC BRAF CCND1 CDC73 CTNNB1
7 mortality/aging MP:0010768 10.41 AIP APC BRAF CCND1 CDC73 CTNNB1
8 immune system MP:0005387 10.38 APC BRAF CCND1 CDC73 CTNNB1 GNAS
9 hematopoietic system MP:0005397 10.37 APC BRAF CCND1 CDC73 CTNNB1 GNAS
10 behavior/neurological MP:0005386 10.36 APC BRAF CCND1 CDC73 CTNNB1 GNAS
11 embryo MP:0005380 10.33 AIP APC BRAF CDC73 CTNNB1 KRAS
12 integument MP:0010771 10.3 AIP APC BRAF CCND1 CDC73 CTNNB1
13 neoplasm MP:0002006 10.28 AIP APC BRAF CCND1 CDC73 CTNNB1
14 craniofacial MP:0005382 10.26 APC BRAF CCND1 CDC73 CTNNB1 GNAS
15 nervous system MP:0003631 10.25 APC BRAF CCND1 CDC73 CTNNB1 GNAS
16 liver/biliary system MP:0005370 10.19 AIP APC BRAF CDC73 CTNNB1 GNAS
17 limbs/digits/tail MP:0005371 10.16 APC BRAF CTNNB1 GNAS KRAS PLAGL1
18 muscle MP:0005369 10.11 APC BRAF CDC73 CTNNB1 GNAS KRAS
19 reproductive system MP:0005389 10.07 APC BRAF CCND1 CDC73 CTNNB1 KRAS
20 hearing/vestibular/ear MP:0005377 10.04 APC BRAF CTNNB1 GNAS KRAS TSHR
21 normal MP:0002873 9.97 APC BRAF CCND1 CTNNB1 GNAS KRAS
22 renal/urinary system MP:0005367 9.97 APC BRAF CDC73 CTNNB1 GNAS KRAS
23 respiratory system MP:0005388 9.85 BRAF CCND1 CDC73 CTNNB1 GNAS KRAS
24 skeleton MP:0005390 9.65 APC BRAF CCND1 CDC73 CTNNB1 GNAS
25 vision/eye MP:0005391 9.23 APC BRAF CCND1 CTNNB1 KRAS MLH1

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 602)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
2
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
3
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
4
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
5
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
6
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
7
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
8
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
9
Magnesium citrate Approved Phase 4,Phase 3,Phase 2 3344-18-1
10
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
11
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
12
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
16
Glucagon Approved Phase 4,Early Phase 1 16941-32-5
17
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
18
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
19
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
20
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
21
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
22
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
23
Parathyroid hormone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9002-64-6
24
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
25
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
27
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 70789204 6442177
28
Simethicone Approved Phase 4,Phase 3,Not Applicable 8050-81-5
29
Pasireotide Approved Phase 4,Phase 2,Phase 3,Phase 1 396091-73-9 9941444
30
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
31
Sodium sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7757-82-6
32
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1 93-14-1 3516
35
Methylene blue Approved, Investigational Phase 4,Phase 3 61-73-4
36
lanreotide Approved Phase 4,Phase 3,Phase 2 108736-35-2
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Cefdinir Approved Phase 4 91832-40-5 6915944
39
Sulfamethoxazole Approved Phase 4 723-46-6 5329
40
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
41
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
42
Cefazolin Approved Phase 4 25953-19-9 33255 656510
43
Codeine Approved, Illicit Phase 4 76-57-3 5284371
44
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
45
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
46
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
47
Dyclonine Approved Phase 4 586-60-7 3180
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
49
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-70-2 271
50
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-81-7 54670067 5785

Interventional clinical trials:

(show top 50) (show all 1413)
# Name Status NCT ID Phase Drugs
1 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
3 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
4 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
5 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
6 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
7 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
8 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
9 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
10 Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
11 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
12 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
13 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
14 Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy Completed NCT01124266 Phase 4
15 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
16 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
17 Effect of Simethicone on Screening Colonoscopy Completed NCT03119168 Phase 4 Simethicone Solution
18 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy Completed NCT02507037 Phase 4 polyethylene glycol
19 Glucagon and Colonoscopy Completed NCT02078726 Phase 4 Glucagon;Placebo
20 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
21 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
22 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
23 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
24 GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Completed NCT02283684 Phase 4
25 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
26 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
27 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
28 Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid. Completed NCT02073552 Phase 4 Polyethylene glycol 4000;Macrogol 3350 plus ascorbic acid
29 Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
30 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
31 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
32 Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid Completed NCT02761213 Phase 4 Oral sulfate solution (OSS);2-L PEG/Asc
33 Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps Completed NCT01133041 Phase 4
34 Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas Recruiting NCT03436004 Phase 4
35 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
36 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
37 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
38 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
39 Dose Individualization of Pemetrexed - IMPROVE-III Recruiting NCT03655834 Phase 4 Pemetrexed
40 Dose Individualization of Pemetrexed - IMPROVE-II Recruiting NCT03655821 Phase 4 Pemetrexed
41 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp Recruiting NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
42 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Active, not recruiting NCT02032784 Phase 4 octreotide
43 Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Active, not recruiting NCT03742232 Phase 4 PEG3350;Macrogol 4000
44 A Comparison of Eleview Versus Hetastarch as Injectate for EMR Active, not recruiting NCT03350217 Phase 4 Eleview;Hetastarch
45 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Active, not recruiting NCT02842749 Phase 4 everolimus
46 Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Not yet recruiting NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
47 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Not yet recruiting NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
48 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Not yet recruiting NCT02832869 Phase 4
49 A Randomized Controlled Trial of Tailored Bowel Preparation Based on A Predictive Model Not yet recruiting NCT03704571 Phase 4 Polyethylene Glycol
50 Clinical Study on Prevention Colorectal Adenomatous Polyp Recurrence After Polypectomy Under Colonoscopy by Xiaoai Jiedu Decoction Not yet recruiting NCT03616444 Phase 4 Xiaoai Jiedu Decoction

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

42
Pituitary, Colon, Thyroid, Lung, Salivary Gland, Prostate, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 10867)
# Title Authors Year
1
Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. ( 30742299 )
2019
2
A case of acromegaly caused by Rathke's cleft cyst mimicking a plurihormonal pituitary adenoma. ( 30862574 )
2019
3
Colon adenoma and adenocarcinoma with clear cell components - two case reports. ( 31077226 )
2019
4
Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma. ( 31080610 )
2019
5
Cancer in a bang: panel next-generation gene sequencing and OncoScan array analysis of a minute colorectal adenocarcinoma and its precursor adenoma. ( 31087409 )
2019
6
Basal Cell Adenoma of the Salivary Gland and Possible Recurrence as Basal Cell Adenocarcinoma in a Black-tailed Prairie Dog (Cynomys ludovicianus). ( 31103053 )
2019
7
Recurrence of adenoma after curative endoscopic submucosal dissection for a rectal intramucosal adenocarcinoma in adenoma. ( 30993167 )
2019
8
An early adenocarcinoma collided with a pyloric gland adenoma in the gastric cardia. ( 31022395 )
2019
9
Villous adenoma coexistent with focal well-differentiated adenocarcinoma of female urethral orifice: A case report and review of literature. ( 31024961 )
2019
10
A Rare Case of Hypertrophic Gastropathy with Adenocarcinoma Arising from a Gastric-type Adenoma. ( 30918187 )
2019
11
Single Photon Emission Computed Tomography/Computed Tomography Detects a Second Ignored Intrathyroidal Parathyroid Adenoma. ( 31040535 )
2019
12
Clival Metastasis of Hepatocellular Carcinoma with an Initial Histopathological Diagnosis of Atypical Pituitary Adenoma. ( 31041159 )
2019
13
Unclassified hepatocellular adenoma expressing ASS1 associated with inflammatory hepatocellular adenomas. ( 31047837 )
2019
14
An anatomic aberration and a surgical challenge: Mediastinal parathyroid adenoma anterior the pericardium. A case report. ( 31048210 )
2019
15
Giant De Novo Pleomorphic Adenoma of Parapharyngeal Space, Can It Cause Spinal Deformity? A Case Report. ( 31053323 )
2019
16
Association of ApoE haplotype with clinical evidence of pituitary adenoma. ( 31054363 )
2019
17
Ectopic Pituitary Adenoma Presenting as a Clival Mass. ( 31058041 )
2019
18
Dysregulated long non‑coding RNAs in pleomorphic adenoma tissues of pleomorphic adenoma gene 1 transgenic mice. ( 31059011 )
2019
19
Transanal submucosal dissection for large lower rectal adenoma using the Thunderbeat® tissue management system- a video vignette. ( 31063624 )
2019
20
Risk Factors of Traditional Serrated Adenoma and Clinicopathological Characteristics of Synchronous Conventional Adenoma. ( 31063737 )
2019
21
Nodular Fasciitis Mimicking Pleomorphic Adenoma. ( 31064246 )
2019
22
A prospective RCT comparing combined chromoendoscopy with water exchange (CWE) vs water exchange (WE) vs air insufflation (AI) in adenoma detection in screening colonoscopy. ( 31065365 )
2019
23
Cardiovascular Outcomes in Autonomous Cortisol Secretion and Nonfunctioning Adrenal Adenoma: A Systematic Review. ( 31065617 )
2019
24
Metastasizing Pleomporphic Adenoma - Case reports and review of literature. ( 31069196 )
2019
25
Silent pituitary plurihormonal adenoma: clinical relevance of immunohistochemical analysis ( 31071255 )
2019
26
Immunohistochemical Staining on an Excision Biopsy Specimen as a Diagnostic Modality for Rare Idiopathic Hepatocellular Adenoma: A Case Report. ( 31073109 )
2019
27
Cushing's Syndrome: A Large Adenoma of Adrenal Gland. ( 31073111 )
2019
28
Non-surgically treated case of nonfunctioning ruptured adrenal adenoma in a patient on hemodialysis. ( 31073864 )
2019
29
Metastatic Pleomorphic Adenoma in the infratemporal fossa and neck following total parotidectomy after 30 years. ( 31079134 )
2019
30
Magnetic Resonance Imaging and Histopathology in a Case of Pleomorphic Adenoma of a Minor Salivary Gland in the Nasal Cavity. ( 31079138 )
2019
31
Giant Brunner's Gland Adenoma Presenting as Upper Gastrointestinal Bleeding in 76 Years Old Male: A Case Report. ( 31080246 )
2019
32
Pleomorphic Adenoma of the Submandibular Gland: A Case Report. ( 31080247 )
2019
33
Reduction of multitasking distractions underlies the higher adenoma detection rate of water exchange compared to air insufflation - blinded analysis of withdrawal phase videos. ( 31080608 )
2019
34
Combined endoscopic submucosal dissection and transanal minimally invasive surgery for the management of lower rectal adenoma extending above the dentate line: A case report. ( 31083160 )
2019
35
FIT Has Similar Yield as Colonoscopy for Colorectal Cancer and Advanced Adenoma Over 10 Years. ( 31083879 )
2019
36
Endoscopic endonasal resection of nonfunctioning pituitary adenoma with radiological calcification. ( 31093846 )
2019
37
Metastasizing Pleomorphic Adenoma: Recurrent PLAG1/HMGA2 Rearrangements and Identification of a Novel HMGA2-TMTC2 Fusion. ( 31094927 )
2019
38
miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma. ( 31096184 )
2019
39
Cuff-assisted versus cap-assisted colonoscopy for adenoma detection: results of a randomized study. ( 31096275 )
2019
40
A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. ( 31097151 )
2019
41
Rare Histological Type of Adenoma of the Nonpigmented Ciliary Epithelium. ( 31097948 )
2019
42
Prophylactic Snare Tip Soft Coagulation and Its Impact on Adenoma Recurrence After Colonic Endoscopic Mucosal Resection. ( 31098871 )
2019
43
Measuring degeneration of the lateral geniculate nuclei from pituitary adenoma compression detected by 7T ultra-high field MRI: a method for predicting vision recovery following surgical decompression of the optic chiasm. ( 31100726 )
2019
44
Impact of moderate versus deep sedation on adenoma detection rate in index average-risk screening colonoscopies. ( 31102644 )
2019
45
Parathyroid adenoma presenting as genu valgum in a child: A rare case report. ( 31102836 )
2019
46
Olfactory results of endoscopic endonasal surgery for pituitary adenoma: A prospective study of 143 patients. ( 31103759 )
2019
47
Association of a New Germline Variant in the MUTYH DNA Glycosylase Gene with Colorectal Adenoma Transformation into Malignancy ( 31104418 )
2019
48
Unusual visual field defect with giant pituitary adenoma. ( 31106815 )
2019
49
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model. ( 31109334 )
2019
50
A rare skin disorder associated with a stoma: intestinal metaplasia and adenoma occurring in a skin ulcer around a colostomy site. ( 31111465 )
2019